RasP21蛋白在腺性膀胱炎和膀胱移行细胞癌中的表达及意义(3)
第1页 |
参见附件(1946KB,3页)。
参考文献:
[1] 刘刚,鲁功成.腺性膀胱炎[J].中华泌尿外科杂志,1997,12(3):186-189.
[2] LANCELIN F,ANIDJAR M,VILLETTE J M,et al.Telomerase activity as a potential marker in preneoplastic bladder lesions[J]. BJU Int,2000, 85: 526.
[3] HEYNS C F,DEKOCK M L,S,KIRSTEN P H,et al.Pelvic lipomatosis asisociated with cystitis glandularis and adenocarcinoma of the bladder[J]. J Urol, 1991,145:364-366.
[4] 孟彦,许纯孝.Ras癌基因与膀胱癌[J].山东医药杂志,2003,43(18):60-62.
[5] DEFEL-JONES D,TATCHELL K,ROINSON L C,et al.Mammalian and yeast ras gene products biological function in their heterologous systems[J].Science, 1985,228:179.
[6] RAHEY M.MCLORMIEK FRANT.A cytoplasmic pratein stimulates normal N-ras P21 GTP ase, but does not affect oncogene mutants[J]. Science,1987, 238:542-550.
[7] 丁华野,皋岚湘,田玉旺.腺性膀胱炎与膀胱移行细胞癌关系的形态学观察[J].诊断病理学杂志,1994,9(2):83-84.
[8] 张淑敏,崔吉吉,畅继武,等.P53和P21在膀胱腺癌与腺性膀胱炎中的表达[J].临床泌尿外科杂志,1998,13:503-505.
[9] 周兴,刘春晓,梅骅,等.RasP21的表达与腺性膀胱炎的生物学转归[J].中华泌尿外科杂志,1997,18:727-728.
[10] CZERNIAK B,DELTCH D,SIMMONS H,et al.H-ras gene codon 12 mutation and DNA ploidy in urinary caricinoma[J]. Cancer J Brit, 1990,62:762.
[11] LEVESQUE P,RAMCHURRON N,SAINI K,et al.Screening of human bladder tumors and urine sediments for the presence of H-ras mutation[J]. Int J Cancer,1993,53:785.
[12] 缪廷杰,王泽.癌基因产物P21表达与膀胱肿瘤生物学行为之间的关系[J].临床泌尿外科杂志,1990,5:156.
[13] 张志根,吕敏,史时芳,等.腺性膀胱炎的诊断和治疗[J].中华泌尿外科杂志,1999,20:96-98.
(收稿日期: 2007-07-09)
[责任编辑 王慧瑾 邓德灵]
注:“本文中所涉及到的图表、注解、公式等内容请以PDF格式阅读原文。”
您现在查看是摘要介绍页,详见PDF附件(1946KB,3页)。